Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01LM012836 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Library of Medicine (NLM) | NIH |
| Columbia University | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this pilot study is to assess the feasibility of using N-of-1 methods in a virtual research study of melatonin intervention for poor sleep quality. Participants (N=60) will be sent a Fitbit device and 3 smart pill bottles, with one containing 3 mg of melatonin, one containing 0.5 mg of melatonin, and the final bottle containing a placebo pill. The first two weeks will be a baseline period, where no supplement is assigned, but data are collected, including self-report of sleep quality and duration and accelerometer-derived sleep and activity data. After successful completion of the baseline period, participants will be randomized to six 2-week intervention blocks of a 3 mg dose melatonin, a 0.5 mg dose melatonin, and a placebo. At the end of the trial, participants will be asked to complete the System Usability Scale, a satisfaction survey (electronic or phone/video call if they are non-responders), and participate in a virtual interview (such as over Microsoft Teams or a phone call) to inform feasibility and acceptability of protocol requirements, study materials, and personalized reports.
The purpose of this pilot study is to assess the feasibility of using N-of-1 methods in a virtual research study; to remotely recruit and enroll participants; to assess the feasibility of using a placebo and to determine the feasibility of the proposed methods used to collect and assess participant adherence and response to a wellness strategy (in this case, melatonin for poor sleep quality). This pilot will help determine if an N-of-1 study design, or what has been termed 'Personalized Trials', can have widespread use in future research and clinical practice to address high public health burdens with a high heterogeneity of response. This pilot study will assess feasibility using a Personalized Trials model to evaluate an individual participant's experience with a wellness strategy for self-reported poor sleep quality. Participants (N=60) will be sent a Fitbit device and 3 smart pill bottles, with one containing 3 mg of melatonin, one containing 0.5 mg of melatonin, and the final bottle containing placebo pills. Participants will be asked several questions a day sent via text message about their sleep quality, as well as their stress, fatigue, concentration, confidence, mood, and pain levels to demonstrate relevant secondary impacts of sleep quality. Participants will also have access to several videos explaining the protocol. The study will take place over the course of 14 weeks. The first two weeks will be a baseline period, where no supplement is assigned, but data are collected, including self-report of sleep quality and duration and accelerometer-derived sleep and activity data. After successful completion of the baseline period, participants will be randomized to six 2-week intervention blocks of a 3 mg dose melatonin, a 0.5 mg dose melatonin, and a placebo. At the end of the 14 weeks, a report containing the individual's observed data will be prepared for each participant and electronically sent to them along with a satisfaction survey (electronic, or phone/video call if they are non-responders).
After the end of the 14-week trial, participants will receive a summary of their observed data in a personalized report. Creating this type of report will help to assess the feasibility of using a N-of-1 trial design through user-acceptability of sleep quality and wellness-related data visualizations, and the ability to choose preferred intervention (if any) based on the data. Participants will be asked to complete the System Usability Scale, a satisfaction survey (electronic or phone/video call if they are non-responders), and participate in a virtual interview (such as over Microsoft Teams or a phone call) to inform feasibility and acceptability of protocol requirements, study materials, and personalized reports.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Melatonin 3 mg | Experimental | Individuals will receive a kit with medication adherence devices containing melatonin 3 mg in one of three smart electronic pill bottles labeled "A," "B," and "C." Participants will not be aware which of the pill bottles contains the 3mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 3 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 3 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total). |
|
| Melatonin 0.5 mg | Active Comparator | Individuals will receive a kit with medication adherence devices containing melatonin 0.5 mg in one of three smart electronic pill bottles labeled "A," "B," and "C." Participants will not be aware which of the pill bottles contains the 0.5 mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 0.5 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 0.5 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total). |
|
| Placebo Pill | Placebo Comparator | Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled "A," "B," and "C." Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Melatonin 3 mg | Dietary Supplement | Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean System Usability Score (SUS) | The SUS is a validated 10-item questionnaire that asks users to score each item on a Likert scale from Strongly Disagree (rating of 1) to Strongly Agree (rating of 5). The SUS will be presented to the participant as addressing the ease of use, complexity, consistency of the Personalized Trials system as a whole, from recruitment to receipt of the report. Individual results are calculated to arrive at a composite measure out of 100. Participant SUS scores will be averaged together and an overall mean will be reported with standard deviation. Higher scored values correlate to a more usable system, and therefore a better outcome. | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
| Participant Satisfaction With Personalized Trial Components | Participants will rate their satisfaction with the Personalized N-of-1 Trial overall and with individual elements of the trial in a satisfaction survey administered following the baseline and intervention periods (14 weeks). Means and standard deviations will be reported for each element of satisfaction. Participants will rate their satisfaction on a scale of 1 to 5, with higher scores indicating greater levels of satisfaction. | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
| Measure | Description | Time Frame |
|---|---|---|
| Within-Participant Difference in Fitbit Device-Recorded Sleep Duration. | Nightly sleep duration will be assessed by a Fitbit wearable device. Sleep duration will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Sleep duration values over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Within-Subject Difference in Self-Reported Sleep Disturbance. | Participants will rate their sleep disturbance using the Insomnia Severity Index (ISI) administered daily during baseline and intervention periods (14 weeks). Items are rated from 0 to 4, with higher scores indicating greater levels of sleep disturbance. Levels of daily sleep disturbance will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in sleep disturbance over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karina Davidson, PhD, MASc | Northwell Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Health System Science | New York | New York | 10022 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41004640 | Derived | Butler MJ, Chandereng T, Ahn H, Slotnick S, Miller D, Perrin A, Rodillas J, Friel CP, Goodwin AM, Cheung YK, Davidson KW. A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment. JMIR Form Res. 2025 Sep 26;9:e58192. doi: 10.2196/58192. | |
| 37535419 | Derived | Butler M, D'Angelo S, Perrin A, Rodillas J, Miller D, Arader L, Chandereng T, Cheung YK, Shechter A, Davidson KW. A Series of Remote Melatonin Supplement Interventions for Poor Sleep: Protocol for a Feasibility Pilot Study for a Series of Personalized (N-of-1) Trials. JMIR Res Protoc. 2023 Aug 3;12:e45313. doi: 10.2196/45313. |
Not provided
Not provided
All collected individual participant data (IPD) will be de-identified and pooled before sharing on the Open Science Framework, along with a data dictionary.
Supporting Information: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF) Time Frame: The study protocol, including the statistical analysis plan, will be made available in addition to the informed consent form following completion of recruitment but prior to publication of any data from the current study. De-identified, pooled individual participant data will be made available within a year of final participant data collection. We anticipate this data to be available on the Open Science Framework platform indefinitely.
Access Criteria: All data and supporting information will be stored on the Open Science Framework, a free web application with no access restrictions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group 1 Personalized Trial | Participants in Group 1 received all three arms of the study in two-week blocks in the following order: 3 mg melatonin, .5 mg melatonin, placebo, placebo, .5 mg melatonin, 3 mg melatonin. |
| FG001 | Group 2 Personalized Trial | Participants in Group 2 received all three arms of the study in two-week blocks in the following order: placebo, .5 mg melatonin, 3 mg melatonin, 3 mg melatonin, .5 mg melatonin, placebo. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Participants offered primary outcome
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group 1 Personalized Trial | Participants in Group 1 received all three arms of the study in two-week blocks in the following order: 3 mg melatonin, .5 mg melatonin, placebo, placebo, .5 mg melatonin, 3 mg melatonin. |
| BG001 | Group 2 Personalized Trial |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean System Usability Score (SUS) | The SUS is a validated 10-item questionnaire that asks users to score each item on a Likert scale from Strongly Disagree (rating of 1) to Strongly Agree (rating of 5). The SUS will be presented to the participant as addressing the ease of use, complexity, consistency of the Personalized Trials system as a whole, from recruitment to receipt of the report. Individual results are calculated to arrive at a composite measure out of 100. Participant SUS scores will be averaged together and an overall mean will be reported with standard deviation. Higher scored values correlate to a more usable system, and therefore a better outcome. | Pre-specified to report results at the whole sample level. Though the study utilizes two groups with two treatment orders, this is done to counter-balance the presentation of treatments (3 mg melatonin, .5 mg melatonin, and placebo). Of the 60 participants enrolled in the trial, all were sent the SUS to evaluate the feasibility and acceptability of the trial. Completed survey measures were received for 57 of the 60 (95.0%) participants who were offered the outcome measures. | Posted | Mean | Standard Deviation | score on a scale | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
Data for each participant were collected over a 14-week period (2-week baseline and 12-week intervention).
Systematic assessment was conducted via a daily survey sent to participants asking if they are experiencing any side effects.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 3 mg Melatonin | Dietary Supplement: Melatonin 3 mg Participants provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | General disorders | Systematic Assessment | Systematic assessment conducted via a daily survey sent to participants asking if they are experiencing any side effects believed to be related to their study pill. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Mark Butler, PhD | Northwell Health | 908-414-0238 | markbutler@northwell.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 12, 2022 | May 2, 2024 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Sep 27, 2022 | May 2, 2024 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D020447 | Parasomnias |
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
| D020919 | Sleep Disorders, Intrinsic |
Not provided
Not provided
| ID | Term |
|---|---|
| D008550 | Melatonin |
| ID | Term |
|---|---|
| D014363 | Tryptamines |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
The study utilizes a multiple crossover design to conduct N-of-1 trials in individuals.
Not provided
Not provided
Participants are blinded to the intervention.
|
| Melatonin 0.5 mg | Dietary Supplement | Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills. |
|
| Cellulose placebo pill | Other | Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills. |
|
| Nightly sleep duration will be assessed consistently via Fitbit device during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Mean Within-Subject Difference in Self-Reported Sleep Quality. | Participants will rate their sleep disturbance using a modified version of the Consensus Sleep Diary administered daily during baseline and intervention periods (14 weeks). Participants will be asked to rate their sleep on a 5-point scale rated from "very poor" to "very good". Levels of daily sleep quality will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period, with higher scores indicating better sleep quality. Changes in sleep quality over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Daily sleep quality will be assessed daily via survey during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Fatigue. | Fatigue will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA fatigue will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA fatigue over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA fatigue will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Stress. | Stress will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0(low) to 10(high). Levels of EMA stress will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA stress over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA stress will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Mean Fitbit Device Adherence Rate. | For each participant, the proportion of days where the Fitbit device was worn will be calculated. Proportion of days where the Fitbit device was worn across all participants will be reported with means and standard deviations. | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
| Mean Participant Adherence to Nightly Melatonin 0.5 mg Supplement. | For each participant, the proportion of days where the melatonin 0.5 mg supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Assessed across the two 14-day treatment periods (28 days total). |
| Mean Participant Adherence to Nightly Melatonin 3 mg Supplement. | For each participant, the proportion of days where the melatonin 3 mg supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Assessed across the two 14-day treatment periods (28 days total). |
| Mean Participant Adherence to Nightly Placebo Supplement. | For each participant, the proportion of days where the placebo supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Assessed across the two 14-day treatment periods (28 days total). |
| Difference in self-reported sleep disturbance will be assessed every two weeks between baseline and intervention periods (14 weeks total). |
| Within-Subject Difference in Self-Reported Side Effects. | Participant self-reported side effects will be assessed utilizing a weekly survey measure. Number of side effects will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate a count of self-reported side effects in each study period. Side effects over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Self-reported side effects will be assessed via weekly survey during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Pain. | . Pain will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their pain on a scale of 0(low) to 10(high). Levels of EMA pain will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA pain over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA pain will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Mood. | Mood will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(poor) to 10(excellent). Levels of EMA mood will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA mood over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA mood will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Concentration. | Concentration will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA concentration will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA concentration over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA concentration will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Ecological Momentary Assessment (EMA) of Confidence. | Confidence will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA confidence will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA confidence over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | EMA confidence will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Within-Subject Difference in Fitbit Device-Recorded Daily Steps. | . Daily step counts will be assessed by a Fitbit device. Daily step counts will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Daily steps values over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Daily steps will be assessed consistently via Fitbit device during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
| Mean Participant Survey Adherence Rate. | For each participant of the proportion of surveys measures completed (both daily and weekly surveys) will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
| Mean Participant Ecological Momentary Assessment (EMA) Adherence Rate. | For each participant of the proportion of EMA measures completed will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
Participants in Group 2 received all three arms of the study in two-week blocks in the following order: placebo, .5 mg melatonin, 3 mg melatonin, 3 mg melatonin, .5 mg melatonin, placebo. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| ID | Title | Description |
|---|---|---|
| OG000 | All Participants | Participants in both treatment order groups are combined for analyses of primary and secondary outcomes. |
|
|
| Primary | Participant Satisfaction With Personalized Trial Components | Participants will rate their satisfaction with the Personalized N-of-1 Trial overall and with individual elements of the trial in a satisfaction survey administered following the baseline and intervention periods (14 weeks). Means and standard deviations will be reported for each element of satisfaction. Participants will rate their satisfaction on a scale of 1 to 5, with higher scores indicating greater levels of satisfaction. | Pre-specified to report results at the whole sample level. Though the study utilizes two groups with two treatment orders, this is done to counter-balance the presentation of treatments (3 mg melatonin, .5 mg melatonin, and placebo). Of the 60 participants enrolled in the trial, all were sent a satisfaction survey to evaluate the feasibility and acceptability of the trial. Completed survey measures were received for 57 of the 60 (95.0%) participants who were offered the outcome measures. | Posted | Mean | Standard Deviation | score on a scale | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
|
|
|
| Secondary | Within-Participant Difference in Fitbit Device-Recorded Sleep Duration. | Nightly sleep duration will be assessed by a Fitbit wearable device. Sleep duration will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Sleep duration values over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Of the 60 enrolled participants, 55 (91.7%) participants had sufficient Fitbit data to include in analyses. | Posted | Mean | Standard Deviation | minutes per night | Nightly sleep duration will be assessed consistently via Fitbit device during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
|
|
|
| Secondary | Mean Within-Subject Difference in Self-Reported Sleep Quality. | Participants will rate their sleep disturbance using a modified version of the Consensus Sleep Diary administered daily during baseline and intervention periods (14 weeks). Participants will be asked to rate their sleep on a 5-point scale rated from "very poor" to "very good". Levels of daily sleep quality will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period, with higher scores indicating better sleep quality. Changes in sleep quality over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Of the 60 enrolled participants, 55 (91.7%) participants had sufficient sleep quality data during the baseline assessment, melatonin .5 mg, and placebo periods, and 54 (90.0%) participants had sufficient sleep quality data during the melatonin 3 mg period to include in analyses. | Posted | Mean | Standard Deviation | score on a scale per day | Daily sleep quality will be assessed daily via survey during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each). |
|
|
|
| Secondary | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Fatigue. | Fatigue will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA fatigue will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA fatigue over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Of the 60 enrolled participants, 55 (91.7%) participants had sufficient EMA data during the baseline assessment, melatonin .5 mg, and placebo periods, and 54 (90.0%) participants had sufficient EMA data during the melatonin 3 mg period to include in analyses. | Posted | Mean | Standard Deviation | units on a scale per period | EMA fatigue will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
|
|
|
| Secondary | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Stress. | Stress will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0(low) to 10(high). Levels of EMA stress will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA stress over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Of the 60 enrolled participants, 55 (91.7%) participants had sufficient EMA data during the baseline assessment, melatonin .5 mg, and placebo periods, and 54 (90.0%) participants had sufficient EMA data during the melatonin 3 mg period to include in analyses. | Posted | Mean | Standard Deviation | units on a scale per period | EMA stress will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). |
|
|
|
| Secondary | Mean Fitbit Device Adherence Rate. | For each participant, the proportion of days where the Fitbit device was worn will be calculated. Proportion of days where the Fitbit device was worn across all participants will be reported with means and standard deviations. | Pre-specified to report results at the whole sample level. Of the 60 enrolled participants, 55 (91.7%) had sufficient Fitbit data across the 98 day study to include in analyses. | Posted | Mean | Standard Deviation | days | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). |
|
|
|
| Secondary | Mean Participant Adherence to Nightly Melatonin 0.5 mg Supplement. | For each participant, the proportion of days where the melatonin 0.5 mg supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Pre-specified to report results at the whole sample level. Of the 60 enrolled participants, 55 (91.7%) had sufficient supplement adherence data across each 28 day study period (3 mg melatonin, .5 mg melatonin, and placebo) to include in analyses. | Posted | Mean | Standard Deviation | days | Assessed across the two 14-day treatment periods (28 days total). |
|
|
|
| Secondary | Mean Participant Adherence to Nightly Melatonin 3 mg Supplement. | For each participant, the proportion of days where the melatonin 3 mg supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Pre-specified to report results at the whole sample level. Of the 60 enrolled participants, 55 (91.7%) had sufficient supplement adherence data across each 28 day study period (3 mg melatonin, .5 mg melatonin, and placebo) to include in analyses. | Posted | Mean | Standard Deviation | days | Assessed across the two 14-day treatment periods (28 days total). |
|
|
|
| Secondary | Mean Participant Adherence to Nightly Placebo Supplement. | For each participant, the proportion of days where the placebo supplement was administered will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Pre-specified to report results at the whole sample level. Of the 60 enrolled participants, 55 (91.7%) had sufficient supplement adherence data across each 28 day study period (3 mg melatonin, .5 mg melatonin, and placebo) to include in analyses. | Posted | Mean | Standard Deviation | days | Assessed across the two 14-day treatment periods (28 days total). |
|
|
|
| Other Pre-specified | Mean Within-Subject Difference in Self-Reported Sleep Disturbance. | Participants will rate their sleep disturbance using the Insomnia Severity Index (ISI) administered daily during baseline and intervention periods (14 weeks). Items are rated from 0 to 4, with higher scores indicating greater levels of sleep disturbance. Levels of daily sleep disturbance will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in sleep disturbance over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | Difference in self-reported sleep disturbance will be assessed every two weeks between baseline and intervention periods (14 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Self-Reported Side Effects. | Participant self-reported side effects will be assessed utilizing a weekly survey measure. Number of side effects will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate a count of self-reported side effects in each study period. Side effects over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | Self-reported side effects will be assessed via weekly survey during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Pain. | . Pain will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their pain on a scale of 0(low) to 10(high). Levels of EMA pain will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA pain over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | EMA pain will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Mood. | Mood will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(poor) to 10(excellent). Levels of EMA mood will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA mood over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | EMA mood will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Concentration. | Concentration will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA concentration will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA concentration over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | EMA concentration will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Ecological Momentary Assessment (EMA) of Confidence. | Confidence will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their fatigue on a scale of 0(low) to 10(high). Levels of EMA confidence will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Changes in EMA confidence over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | EMA confidence will be assessed 3 times daily via text message during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Within-Subject Difference in Fitbit Device-Recorded Daily Steps. | . Daily step counts will be assessed by a Fitbit device. Daily step counts will be aggregated within the baseline assessment period and in each of the intervention periods (3 mg melatonin, 0.5 mg melatonin, placebo) to generate an overall mean and standard deviation for each period. Daily steps values over the course of the study will be evaluated using Generalized Linear Mixed Model analyses. | Not Posted | Daily steps will be assessed consistently via Fitbit device during the baseline assessment period (2 weeks) and during each of the 6 intervention periods (2 weeks each, 12 weeks total). | Participants |
| Other Pre-specified | Mean Participant Survey Adherence Rate. | For each participant of the proportion of surveys measures completed (both daily and weekly surveys) will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Not Posted | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). | Participants |
| Other Pre-specified | Mean Participant Ecological Momentary Assessment (EMA) Adherence Rate. | For each participant of the proportion of EMA measures completed will be calculated. Proportion of days adherent across all participants will be reported with means and standard deviations. | Not Posted | Assessed once after the results report has been sent to the participant after completion of the trial (14 weeks from baseline). | Participants |
| 0 |
| 60 |
| 0 |
| 60 |
| 3 |
| 60 |
| EG001 | .5 mg Melatonin | Dietary Supplement: Melatonin 0.5 mg Participants provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills. | 0 | 60 | 0 | 60 | 0 | 60 |
| EG002 | Placebo | Cellulose placebo pill Participants provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills. | 0 | 60 | 0 | 60 | 0 | 60 |
|
Not provided
Not provided
Not provided
| D020920 | Dyssomnias |
| D006571 | Heterocyclic Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
|
| "Text messaging for survey questions." |
|
| "Use of the Fitbit to track your activity and sleep." |
|
| "Presentation of your results." |
|